8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 25, 2020)

Filed March 25, 2020For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb (BMY) filed an 8-K on March 25, 2020, to announce the posting of an Investor Fact Sheet on its website concerning COVID-19. This fact sheet, dated March 25, 2020, and attached as Exhibit 99.1, provides information relevant to investors regarding the company's approach and preparedness related to the global pandemic. Investors should refer to the company's website for the detailed content of this fact sheet, as it is intended to address potential concerns and provide updates during this unprecedented period. While the 8-K filing itself is brief and primarily serves as a notification of the fact sheet's availability, the underlying document is critical for understanding BMY's perspective on COVID-19's impact on its operations, supply chain, clinical trials, and overall business strategy. This proactive communication aims to maintain transparency and manage investor expectations during a period of significant market uncertainty.

Key Highlights

  • 1BMY has issued an Investor Fact Sheet specifically addressing COVID-19.
  • 2The fact sheet was posted on the company's website (www.bms.com) on March 25, 2020.
  • 3The filing includes the COVID-19 Investor Fact Sheet as Exhibit 99.1.
  • 4This communication aims to inform investors about the company's position and plans regarding the pandemic.
  • 5The event date for this disclosure was March 24, 2020, with the filing made on March 25, 2020.

Frequently Asked Questions

The primary purpose of this 8-K filing is to formally announce and provide access to an Investor Fact Sheet released by Bristol-Myers Squibb (BMY) concerning COVID-19. The fact sheet offers information relevant to investors regarding the company's response and considerations related to the pandemic.

The COVID-19 Investor Fact Sheet can be found on Bristol-Myers Squibb's official website at www.bms.com. It is also attached as Exhibit 99.1 to this Current Report on Form 8-K.

Given the timing (March 2020) and the nature of the document, the Investor Fact Sheet likely addresses the potential impact of COVID-19 on BMY's operations, supply chain, clinical trials, ongoing research and development, and financial outlook. It may also outline the company's business continuity plans and safety measures.

No, this 8-K filing does not contain new financial results or forward-looking guidance. It solely serves as a notification about the availability of the COVID-19 Investor Fact Sheet, which contains information related to the pandemic's impact.